Huadong Medicine’s clinical trial application for injectable HDM2024 drug has been approved by the US FDA
March 12, 2026
Source: drugdu
38
March 11, Huadong Medicine...(000963) issued an announcement stating that its wholly-owned subsidiary, Hangzhou Sino-American East China Pharmaceutical Co., Ltd. (hereinafter referred to as "Sino-American East China"), received a notification from the U.S. Food and Drug Administration (hereinafter referred to as "FDA") that the clinical trial application for injectable HDM2024 submitted by Sino-American East China has been approved by the U.S. FDA and can be carried out in the United States for Phase I clinical trials, with the indication being advanced solid tumors.
Huadong Medicine stated that the approval of the US clinical trial of injectable HDM2024 is another important step in the product's development process and will further enhance the company's core competitiveness in the field of oncology treatment.
https://finance.eastmoney.com/a/202603113668988846.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- SHR-9803 for Injection Approved for Clinical Trials March 12, 2026
- Invests 5 million yuan to participate in the establishment of an investment fund to expand into the biopharmaceutical field March 12, 2026
- Its subsidiary’s Class 1 innovative drug TQB3205 has been approved for clinical trials, intended for the treatment of advanced malignant tumors. March 12, 2026
- Novogene® has been approved, making its global debut in China! March 10, 2026
- CSPC indacaterol mometasone inhalation powder has been approved for clinical trials in China. March 10, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
